You are here

Study Sees No Link Between Antibiotics in Early Pregnancy and Birth Defects

Researchers looked for risks among women prescribed drugs such as azithromycin

A Canadian study did not find any association between two common types of antibiotics taken during pregnancy and a higher risk of adverse effects to the baby.

According to a HealthDay report, four out of 10 pregnant women are prescribed antibiotics, with azithromycin and clarithromycin being the most common. They belong to a class of drugs called macrolides.

"With penicillin, macrolides are amongst the most used medications in the general population and in pregnancy. However, debate remained on whether it is the infections or in fact the macrolides used to treat them that put women and their unborn child at greater risk of adverse pregnancy outcomes, including birth defects," said study co-leader Anick Berard, a professor of pharmacy at the University of Montreal. "We therefore aimed to estimate the risk of major congenital malformations after fetal exposure to the two most commonly used macrolides, and failed to find any."

The researchers reviewed more than 135,000 pregnancies in the province of Quebec. About 2% of the women were prescribed macrolides during the first trimester of pregnancy. Major birth defects occurred in about 10% of the babies. The researchers did not find an association between the use of macrolides and the risk of birth defects, according to the study published October 30 in the journal Pharmacoepidemiology and Drug Safety.

The researchers said previous confusion about the safety of macrolides during pregnancy might stem from several overlooked factors. For example, azithromycin is often used to treat chlamydia infections, which are associated with birth defects, the researchers said. They added that further studies are needed to confirm the safety of antibiotics less often prescribed to pregnant women.

Source: HealthDay, October 30, 2015.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids